[Explainer] why an oral non-peptide escapes the absorption problem entirely
The one-line version is the title: why an oral non-peptide escapes the absorption problem entirely. The rest is why.
The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.
Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.
Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.
Corrections welcome, especially the pedantic ones. Pedantry is how this board earns its reputation.
best — the order this archive was captured in
Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random.
Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.
GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.
Right — mechanism gives you a direction. It never gives you an effect size and people use it as though it does.
Not convinced by the linearity assumption. Dose-response in this class is not linear and the trials show it.
Left up and flaired Explainer. This is the standard of post the board was created for.
tolerance to the gastric effect develops, appetite effect largely persists
Yes. The discussion section is where the authors say what they actually think, and almost nobody here reads it.
Small fix — it slows gastric emptying, it does not halt it, and the distinction matters for the mechanism you are proposing.
Same view. Tolerance developing to the gastric effect while the appetite effect persists explains most of what the side-effect board reports.